Want to join the conversation?
$ABBV adjusted R&D was 15.5% of sales, reflecting funding action supporting the pipeline and the impact of both Stemcentrx transaction and the Boehringer Ingelheim collaboration. Adjusted SG&A was 22.2% of the sales in 2Q16, down 290 BPs from the prior year. Adjusted operating margin was 43.9% of sales, down 30 BPs relative to 2Q15.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.